TORONTO, Nov. 2, 2015 /PRNewswire/ - Transition
Therapeutics Inc. ("Transition" or the "Company") (NASDAQ:
TTHI, TSX: TTH) will hold a conference call on Tuesday, November 10th, 2015 at 4:30 P.M. EST to discuss First Quarter Fiscal
2016 financial results. Dr. Tony
Cruz, Chairman and Chief Executive Officer of the Company,
will host the call. Transition will announce its financial
results for this period in a press release to be issued prior to
the call. In order to participate in the conference call,
please call (888) 227-6492 (North
America) and (303) 223-2685 (International). A webcast is
also available at www.transitiontherapeutics.com A replay of
the conference call will be available on Transition's website for
seven days following the call.
About Transition
Transition is a biopharmaceutical
development company, advancing novel therapeutics for CNS and
metabolic disease indications. The Company's wholly-owned
subsidiary, Transition Therapeutics Ireland Limited is developing
CNS drug candidate ELND005 for the treatment of Alzheimer's disease
and Down syndrome. Transition's lead metabolic drug candidate
is TT401 (LY2944876) for the treatment of type 2 diabetes and
accompanying obesity. The Company's shares are listed on the NASDAQ
under the symbol "TTHI" and the Toronto Stock Exchange under the
symbol "TTH". For additional information about the Company, please
visit www.transitiontherapeutics.com.
Notice to Readers: Information contained in our press releases
should be considered accurate only as of the date of the release
and may be superseded by more recent information we have disclosed
in later press releases, filings with the OSC, SEC or otherwise.
Except for historical information, this press release may contain
forward-looking statements, relating to expectations, plans or
prospects for Transition, including conducting clinical trials and
potential efficacy of its products. These statements are based upon
the current expectations and beliefs of Transition's management and
are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include
factors beyond Transition's control and the risk factors and other
cautionary statements discussed in Transition's quarterly and
annual filings with the Canadian commissions.
SOURCE Transition Therapeutics Inc.